估算使用贝伐珠单抗治疗渗出性年龄相关性黄斑变性为 Medicare 和患者节省的费用
该回顾性趋势研究利用 2008 年及 2012 至 2015 年 Medicare 按服务收费受益人索赔数据,估算以贝伐珠单抗替代雷珠单抗和阿柏西普治疗渗出性年龄相关性黄斑变性(AMD)的费用节省。约 30% 符合 Medicare 资格者参加 Medicare Advantage 计划未纳入分析,故该金额低估了实际节省。
要点
- 约 30% 符合 Medicare 资格者参加 Medicare Advantage 计划未纳入分析,故实际节省被低估。
- 若纳入糖尿病黄斑水肿和视网膜静脉阻塞等诊断类别,贝伐珠单抗还可带来额外节省。
研究设计与样本
- 回顾性趋势研究,利用 2012 至 2015 年 Medicare Provider Utilization and Payment Data 中按服务收费受益人索赔数据及 2008 年 100% 按服务收费 Part B Medicare Claims File。
- 主要结局指标为 Medicare 支出,按玻璃体腔注射的 CPT 代码 67028 和血管内皮生长因子抑制剂的治疗特异性 J 代码(J0178、J2778、J9035、J3490 和 J3590)追踪。
主要发现
- 约 30% 符合 Medicare 资格者参加 Medicare Advantage 计划未纳入分析,故该金额低估了 Medicare 提供者的实际费用节省。
临床怎么用
- 原文未据此给出推荐。
局限性
- 约 30% 符合 Medicare 资格者参加 Medicare Advantage 计划未纳入分析,故该金额低估了 Medicare 提供者的实际费用节省。
- 本研究未纳入糖尿病黄斑水肿和视网膜静脉阻塞等诊断类别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Medicare cost savings from the use of bevacizumab in the United States for the treatment of exudative age-related macular degeneration (AMD) were estimated by replacing the use of bevacizumab with ranibizumab and aflibercept. DESIGN: Retrospective trend study. METHODS: Main outcome measures were spending by Medicare as tracked by Current Procedural Terminology (CPT) codes for intravitreal injections (67028) and treatment-specific J-codes (J0178, J2778, J9035, J3490, and J3590) for inhibitors of vascular endothelial growth factor. These claims were identified from the Medicare Provider Utilization and Payment Data from the Centers for Medicare and Medicaid Services among fee-for-service (FFS) Medicare beneficiaries from 2012 to 2015. The 2008 claims were acquired from the 100% fee-for-service (FFS) Part B Medicare Claims File. RESULTS: The use of bevacizumab from 2008 to 2015 resulted in an estimated savings of $17.3 billion, which corresponded to a $13.8 billion savings to Medicare and a $3.5 billion savings to patients. This amount underestimated the actual cost savings to Medicare providers, since approximately 30% of Medicare-eligible recipients received care within Medicare Advantage plans and were not included in this analysis. CONCLUSIONS: The cost savings from the use of bevacizumab from 2008 to 2015 for Medicare fee-for-service patients undergoing treatment for exudative AMD was estimated at $17.3 billion. Additional savings over the $17.3 billion would have accrued from the use of bevacizumab if diagnostic categories such as diabetic macular edema and retinal vein occlusion were included in this study.
引用
- Rosenfeld PJ, Windsor MA, Feuer WJ, et al. Estimating Medicare and Patient Savings From the Use of Bevacizumab for the Treatment of Exudative Age-related Macular Degeneration. Am J Ophthalmol. 2018. PMID: 29655642. doi:10.1016/j.ajo.2018.04.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。